nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—Erlotinib—kidney cancer	0.198	1	CrCtD
Vandetanib—thyroid cancer—kidney cancer	0.14	1	CtDrD
Vandetanib—Protein Kinase Inhibitors—Temsirolimus—kidney cancer	0.0913	0.344	CiPCiCtD
Vandetanib—Gefitinib—Erlotinib—kidney cancer	0.0849	1	CrCrCtD
Vandetanib—Protein Kinase Inhibitors—Sunitinib—kidney cancer	0.0692	0.261	CiPCiCtD
Vandetanib—Protein Kinase Inhibitors—Pazopanib—kidney cancer	0.0524	0.198	CiPCiCtD
Vandetanib—Protein Kinase Inhibitors—Everolimus—kidney cancer	0.0524	0.198	CiPCiCtD
Vandetanib—KDR—kidney cancer	0.0373	0.541	CbGaD
Vandetanib—VEGFA—kidney cancer	0.0316	0.459	CbGaD
Vandetanib—BMPR1B—Pazopanib—kidney cancer	0.00659	0.0402	CbGbCtD
Vandetanib—FLT4—Pazopanib—kidney cancer	0.00551	0.0336	CbGbCtD
Vandetanib—PLK4—Pazopanib—kidney cancer	0.00551	0.0336	CbGbCtD
Vandetanib—KDR—Pazopanib—kidney cancer	0.00476	0.029	CbGbCtD
Vandetanib—LTK—Erlotinib—kidney cancer	0.0047	0.0287	CbGbCtD
Vandetanib—MKNK1—Erlotinib—kidney cancer	0.0047	0.0287	CbGbCtD
Vandetanib—EPHB6—Pazopanib—kidney cancer	0.00421	0.0257	CbGbCtD
Vandetanib—LYN—Pazopanib—kidney cancer	0.00421	0.0257	CbGbCtD
Vandetanib—SLK—Erlotinib—kidney cancer	0.00393	0.024	CbGbCtD
Vandetanib—MKNK1—Sorafenib—kidney cancer	0.00382	0.0233	CbGbCtD
Vandetanib—STK10—Pazopanib—kidney cancer	0.00378	0.0231	CbGbCtD
Vandetanib—LCK—Pazopanib—kidney cancer	0.00344	0.021	CbGbCtD
Vandetanib—PDGFRB—Pazopanib—kidney cancer	0.00344	0.021	CbGbCtD
Vandetanib—MAP2K5—Pazopanib—kidney cancer	0.00344	0.021	CbGbCtD
Vandetanib—FLT3—Erlotinib—kidney cancer	0.0034	0.0207	CbGbCtD
Vandetanib—FLT4—Sorafenib—kidney cancer	0.0032	0.0195	CbGbCtD
Vandetanib—MAP3K19—Pazopanib—kidney cancer	0.00317	0.0193	CbGbCtD
Vandetanib—TYRO3—Sunitinib—kidney cancer	0.0031	0.0189	CbGbCtD
Vandetanib—AXL—Sunitinib—kidney cancer	0.0031	0.0189	CbGbCtD
Vandetanib—IRAK4—Sunitinib—kidney cancer	0.0031	0.0189	CbGbCtD
Vandetanib—FYN—Sunitinib—kidney cancer	0.0031	0.0189	CbGbCtD
Vandetanib—EPHA6—Erlotinib—kidney cancer	0.003	0.0183	CbGbCtD
Vandetanib—KDR—Sorafenib—kidney cancer	0.00276	0.0168	CbGbCtD
Vandetanib—RET—Sorafenib—kidney cancer	0.00276	0.0168	CbGbCtD
Vandetanib—FLT3—Sorafenib—kidney cancer	0.00276	0.0168	CbGbCtD
Vandetanib—ABL2—Erlotinib—kidney cancer	0.0027	0.0165	CbGbCtD
Vandetanib—STK10—Erlotinib—kidney cancer	0.0027	0.0165	CbGbCtD
Vandetanib—EGFR—Erlotinib—kidney cancer	0.0027	0.0165	CbGbCtD
Vandetanib—SLK—Sunitinib—kidney cancer	0.00259	0.0158	CbGbCtD
Vandetanib—FLT4—Sunitinib—kidney cancer	0.00259	0.0158	CbGbCtD
Vandetanib—MAP4K5—Sunitinib—kidney cancer	0.00259	0.0158	CbGbCtD
Vandetanib—YES1—Sunitinib—kidney cancer	0.00259	0.0158	CbGbCtD
Vandetanib—PLK4—Sunitinib—kidney cancer	0.00259	0.0158	CbGbCtD
Vandetanib—MAP2K5—Erlotinib—kidney cancer	0.00246	0.015	CbGbCtD
Vandetanib—EPHA6—Sorafenib—kidney cancer	0.00244	0.0149	CbGbCtD
Vandetanib—EPHB6—Sorafenib—kidney cancer	0.00244	0.0149	CbGbCtD
Vandetanib—MAP3K19—Erlotinib—kidney cancer	0.00226	0.0138	CbGbCtD
Vandetanib—KDR—Sunitinib—kidney cancer	0.00224	0.0136	CbGbCtD
Vandetanib—FGR—Sunitinib—kidney cancer	0.00224	0.0136	CbGbCtD
Vandetanib—RET—Sunitinib—kidney cancer	0.00224	0.0136	CbGbCtD
Vandetanib—FLT3—Sunitinib—kidney cancer	0.00224	0.0136	CbGbCtD
Vandetanib—STK10—renal vein—kidney cancer	0.0022	0.173	CbGeAlD
Vandetanib—STK10—Sorafenib—kidney cancer	0.0022	0.0134	CbGbCtD
Vandetanib—PDGFRB—Sorafenib—kidney cancer	0.002	0.0122	CbGbCtD
Vandetanib—MAP2K5—Sorafenib—kidney cancer	0.002	0.0122	CbGbCtD
Vandetanib—BLK—Sunitinib—kidney cancer	0.00198	0.0121	CbGbCtD
Vandetanib—EPHB6—Sunitinib—kidney cancer	0.00198	0.0121	CbGbCtD
Vandetanib—ABL1—Erlotinib—kidney cancer	0.00195	0.0119	CbGbCtD
Vandetanib—MAP3K19—Sorafenib—kidney cancer	0.00184	0.0112	CbGbCtD
Vandetanib—STK10—Sunitinib—kidney cancer	0.00178	0.0108	CbGbCtD
Vandetanib—MAP2K5—Sunitinib—kidney cancer	0.00162	0.00987	CbGbCtD
Vandetanib—PDGFRB—Sunitinib—kidney cancer	0.00162	0.00987	CbGbCtD
Vandetanib—MAP3K19—Sunitinib—kidney cancer	0.00149	0.00907	CbGbCtD
Vandetanib—STK10—renal artery—kidney cancer	0.00148	0.116	CbGeAlD
Vandetanib—ABCC1—Dactinomycin—kidney cancer	0.000854	0.0052	CbGbCtD
Vandetanib—ORM1—Erlotinib—kidney cancer	0.000731	0.00445	CbGbCtD
Vandetanib—ABCG2—Pazopanib—kidney cancer	0.000625	0.00381	CbGbCtD
Vandetanib—ABCC1—Paclitaxel—kidney cancer	0.00061	0.00372	CbGbCtD
Vandetanib—ABCG2—Dactinomycin—kidney cancer	0.000572	0.00348	CbGbCtD
Vandetanib—ABCC1—Vinblastine—kidney cancer	0.000535	0.00326	CbGbCtD
Vandetanib—ABCC1—Vincristine—kidney cancer	0.000526	0.00321	CbGbCtD
Vandetanib—FMO3—urine—kidney cancer	0.000481	0.0377	CbGeAlD
Vandetanib—ABCG2—Erlotinib—kidney cancer	0.000446	0.00272	CbGbCtD
Vandetanib—ABCG2—Paclitaxel—kidney cancer	0.000408	0.00249	CbGbCtD
Vandetanib—CYP3A4—Everolimus—kidney cancer	0.00038	0.00232	CbGbCtD
Vandetanib—ABCG2—Sorafenib—kidney cancer	0.000363	0.00221	CbGbCtD
Vandetanib—ABCG2—Vincristine—kidney cancer	0.000352	0.00214	CbGbCtD
Vandetanib—ABCC1—Doxorubicin—kidney cancer	0.000329	0.002	CbGbCtD
Vandetanib—ALB—Erlotinib—kidney cancer	0.000307	0.00187	CbGbCtD
Vandetanib—ABCG2—Sunitinib—kidney cancer	0.000294	0.00179	CbGbCtD
Vandetanib—CYP3A4—Temsirolimus—kidney cancer	0.000257	0.00157	CbGbCtD
Vandetanib—PTK6—renal system—kidney cancer	0.000231	0.0181	CbGeAlD
Vandetanib—Afatinib—ERBB2—kidney cancer	0.00023	0.264	CrCbGaD
Vandetanib—Bosutinib—SRMS—kidney cancer	0.00023	0.264	CrCbGaD
Vandetanib—ABCG2—Doxorubicin—kidney cancer	0.00022	0.00134	CbGbCtD
Vandetanib—EPHA6—gonad—kidney cancer	0.000173	0.0135	CbGeAlD
Vandetanib—PLK4—gonad—kidney cancer	0.000171	0.0134	CbGeAlD
Vandetanib—TYRO3—gonad—kidney cancer	0.00016	0.0126	CbGeAlD
Vandetanib—RIPK2—nephron tubule—kidney cancer	0.000151	0.0118	CbGeAlD
Vandetanib—VEGFA—nephron tubule—kidney cancer	0.000151	0.0118	CbGeAlD
Vandetanib—FMO1—nephron tubule—kidney cancer	0.00015	0.0117	CbGeAlD
Vandetanib—Bosutinib—LRRK2—kidney cancer	0.000148	0.17	CrCbGaD
Vandetanib—ERBB3—nephron tubule—kidney cancer	0.000145	0.0113	CbGeAlD
Vandetanib—FLT3—gonad—kidney cancer	0.000136	0.0107	CbGeAlD
Vandetanib—FMO1—renal system—kidney cancer	0.000136	0.0107	CbGeAlD
Vandetanib—CYP3A4—Pazopanib—kidney cancer	0.000135	0.000823	CbGbCtD
Vandetanib—STK35—gonad—kidney cancer	0.000133	0.0105	CbGeAlD
Vandetanib—STK35—cardiac atrium—kidney cancer	0.000133	0.0104	CbGeAlD
Vandetanib—FMO1—kidney—kidney cancer	0.000132	0.0103	CbGeAlD
Vandetanib—ERBB3—renal system—kidney cancer	0.000131	0.0103	CbGeAlD
Vandetanib—FLT4—cortex of kidney—kidney cancer	0.00013	0.0102	CbGeAlD
Vandetanib—VEGFA—cortex of kidney—kidney cancer	0.000129	0.0101	CbGeAlD
Vandetanib—SLK—nephron tubule—kidney cancer	0.000129	0.0101	CbGeAlD
Vandetanib—FMO1—cortex of kidney—kidney cancer	0.000128	0.01	CbGeAlD
Vandetanib—ERBB3—kidney—kidney cancer	0.000127	0.00996	CbGeAlD
Vandetanib—CYP3A4—urine—kidney cancer	0.000126	0.00985	CbGeAlD
Vandetanib—FYN—nephron tubule—kidney cancer	0.000125	0.00979	CbGeAlD
Vandetanib—RIPK2—cardiac atrium—kidney cancer	0.000123	0.00964	CbGeAlD
Vandetanib—VEGFA—cardiac atrium—kidney cancer	0.000123	0.00961	CbGeAlD
Vandetanib—RET—renal system—kidney cancer	0.000122	0.00955	CbGeAlD
Vandetanib—RET—kidney—kidney cancer	0.000118	0.00923	CbGeAlD
Vandetanib—MKNK1—cortex of kidney—kidney cancer	0.000116	0.0091	CbGeAlD
Vandetanib—AXL—cortex of kidney—kidney cancer	0.000114	0.00896	CbGeAlD
Vandetanib—FYN—renal system—kidney cancer	0.000114	0.0089	CbGeAlD
Vandetanib—YES1—nephron tubule—kidney cancer	0.000113	0.00884	CbGeAlD
Vandetanib—ERBB3—Vinblastine—Vincristine—kidney cancer	0.000112	0.292	CbGdCrCtD
Vandetanib—TEK—renal system—kidney cancer	0.000111	0.0087	CbGeAlD
Vandetanib—MKNK1—gonad—kidney cancer	0.000111	0.00867	CbGeAlD
Vandetanib—MKNK1—cardiac atrium—kidney cancer	0.00011	0.00866	CbGeAlD
Vandetanib—SLK—cortex of kidney—kidney cancer	0.00011	0.00862	CbGeAlD
Vandetanib—FYN—kidney—kidney cancer	0.00011	0.00861	CbGeAlD
Vandetanib—AXL—gonad—kidney cancer	0.000109	0.00853	CbGeAlD
Vandetanib—AXL—cardiac atrium—kidney cancer	0.000109	0.00852	CbGeAlD
Vandetanib—TEK—kidney—kidney cancer	0.000107	0.00841	CbGeAlD
Vandetanib—FYN—cortex of kidney—kidney cancer	0.000107	0.00838	CbGeAlD
Vandetanib—Bosutinib—ALK—kidney cancer	0.000106	0.121	CrCbGaD
Vandetanib—SLK—cardiac atrium—kidney cancer	0.000105	0.0082	CbGeAlD
Vandetanib—MAP4K5—cortex of kidney—kidney cancer	0.000105	0.00819	CbGeAlD
Vandetanib—TEK—cortex of kidney—kidney cancer	0.000105	0.00819	CbGeAlD
Vandetanib—YES1—renal system—kidney cancer	0.000103	0.00803	CbGeAlD
Vandetanib—FYN—cardiac atrium—kidney cancer	0.000102	0.00797	CbGeAlD
Vandetanib—STK10—renal system—kidney cancer	0.000102	0.00796	CbGeAlD
Vandetanib—EPHB6—cortex of kidney—kidney cancer	9.99e-05	0.00783	CbGeAlD
Vandetanib—KDR—nephron tubule—kidney cancer	9.98e-05	0.00782	CbGeAlD
Vandetanib—MAP4K5—gonad—kidney cancer	9.95e-05	0.0078	CbGeAlD
Vandetanib—TEK—cardiac atrium—kidney cancer	9.94e-05	0.00779	CbGeAlD
Vandetanib—MAP4K5—cardiac atrium—kidney cancer	9.94e-05	0.00779	CbGeAlD
Vandetanib—YES1—kidney—kidney cancer	9.91e-05	0.00777	CbGeAlD
Vandetanib—SRC—renal system—kidney cancer	9.86e-05	0.00773	CbGeAlD
Vandetanib—STK10—kidney—kidney cancer	9.82e-05	0.0077	CbGeAlD
Vandetanib—YES1—cortex of kidney—kidney cancer	9.65e-05	0.00756	CbGeAlD
Vandetanib—CYP3A4—Erlotinib—kidney cancer	9.63e-05	0.000587	CbGbCtD
Vandetanib—SRC—kidney—kidney cancer	9.53e-05	0.00747	CbGeAlD
Vandetanib—EPHB6—cardiac atrium—kidney cancer	9.5e-05	0.00745	CbGeAlD
Vandetanib—YES1—gonad—kidney cancer	9.19e-05	0.0072	CbGeAlD
Vandetanib—YES1—cardiac atrium—kidney cancer	9.18e-05	0.0072	CbGeAlD
Vandetanib—STK10—gonad—kidney cancer	9.11e-05	0.00714	CbGeAlD
Vandetanib—KDR—renal system—kidney cancer	9.07e-05	0.00711	CbGeAlD
Vandetanib—SRC—gonad—kidney cancer	8.84e-05	0.00693	CbGeAlD
Vandetanib—SRC—cardiac atrium—kidney cancer	8.83e-05	0.00692	CbGeAlD
Vandetanib—CYP3A4—Paclitaxel—kidney cancer	8.82e-05	0.000537	CbGbCtD
Vandetanib—KDR—kidney—kidney cancer	8.77e-05	0.00687	CbGeAlD
Vandetanib—KDR—cortex of kidney—kidney cancer	8.54e-05	0.00669	CbGeAlD
Vandetanib—MAP2K5—cortex of kidney—kidney cancer	8.54e-05	0.00669	CbGeAlD
Vandetanib—KDR—cardiac atrium—kidney cancer	8.12e-05	0.00637	CbGeAlD
Vandetanib—MAP2K5—cardiac atrium—kidney cancer	8.12e-05	0.00637	CbGeAlD
Vandetanib—PDGFRB—renal system—kidney cancer	7.85e-05	0.00615	CbGeAlD
Vandetanib—CYP3A4—Sorafenib—kidney cancer	7.83e-05	0.000477	CbGbCtD
Vandetanib—CYP3A4—Vinblastine—kidney cancer	7.73e-05	0.000471	CbGbCtD
Vandetanib—ABL1—nephron tubule—kidney cancer	7.7e-05	0.00603	CbGeAlD
Vandetanib—CYP3A4—Vincristine—kidney cancer	7.6e-05	0.000463	CbGbCtD
Vandetanib—PDGFRB—kidney—kidney cancer	7.59e-05	0.00595	CbGeAlD
Vandetanib—PDGFRB—cortex of kidney—kidney cancer	7.39e-05	0.00579	CbGeAlD
Vandetanib—PDGFRB—gonad—kidney cancer	7.04e-05	0.00552	CbGeAlD
Vandetanib—PDGFRB—cardiac atrium—kidney cancer	7.03e-05	0.00551	CbGeAlD
Vandetanib—ABL1—renal system—kidney cancer	7e-05	0.00549	CbGeAlD
Vandetanib—ABL1—kidney—kidney cancer	6.77e-05	0.0053	CbGeAlD
Vandetanib—ABL1—cortex of kidney—kidney cancer	6.59e-05	0.00516	CbGeAlD
Vandetanib—CYP3A4—Sunitinib—kidney cancer	6.35e-05	0.000387	CbGbCtD
Vandetanib—ABL1—gonad—kidney cancer	6.28e-05	0.00492	CbGeAlD
Vandetanib—ABL1—cardiac atrium—kidney cancer	6.27e-05	0.00491	CbGeAlD
Vandetanib—PLK4—Epirubicin—Doxorubicin—kidney cancer	6e-05	0.157	CbGdCrCtD
Vandetanib—PLK4—Idarubicin—Doxorubicin—kidney cancer	6e-05	0.157	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Doxorubicin—kidney cancer	5.04e-05	0.132	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Doxorubicin—kidney cancer	5.04e-05	0.132	CbGdCrCtD
Vandetanib—ABL1—Epirubicin—Doxorubicin—kidney cancer	5.04e-05	0.132	CbGdCrCtD
Vandetanib—ABCC1—cortex of kidney—kidney cancer	5.02e-05	0.00393	CbGeAlD
Vandetanib—ABCG2—nephron tubule—kidney cancer	4.85e-05	0.00381	CbGeAlD
Vandetanib—ABCC1—cardiac atrium—kidney cancer	4.77e-05	0.00374	CbGeAlD
Vandetanib—CYP3A4—Doxorubicin—kidney cancer	4.75e-05	0.00029	CbGbCtD
Vandetanib—Erlotinib—CYP1A1—kidney cancer	4.4e-05	0.0505	CrCbGaD
Vandetanib—Afatinib—ABCB1—kidney cancer	3.31e-05	0.038	CrCbGaD
Vandetanib—CYP3A4—renal system—kidney cancer	3.07e-05	0.00241	CbGeAlD
Vandetanib—CYP3A4—kidney—kidney cancer	2.97e-05	0.00233	CbGeAlD
Vandetanib—Gefitinib—CYP1A1—kidney cancer	2.75e-05	0.0316	CrCbGaD
Vandetanib—Erlotinib—ABCB1—kidney cancer	2.34e-05	0.0268	CrCbGaD
Vandetanib—Gefitinib—ABCB1—kidney cancer	1.46e-05	0.0168	CrCbGaD
Vandetanib—Bosutinib—ABCB1—kidney cancer	1.44e-05	0.0165	CrCbGaD
Vandetanib—Dizziness—Erlotinib—kidney cancer	8.98e-06	0.000254	CcSEcCtD
Vandetanib—Vomiting—Everolimus—kidney cancer	8.95e-06	0.000253	CcSEcCtD
Vandetanib—Urethral disorder—Capecitabine—kidney cancer	8.94e-06	0.000253	CcSEcCtD
Vandetanib—Paraesthesia—Vincristine—kidney cancer	8.93e-06	0.000252	CcSEcCtD
Vandetanib—Dermatitis bullous—Doxorubicin—kidney cancer	8.89e-06	0.000251	CcSEcCtD
Vandetanib—Rash—Everolimus—kidney cancer	8.87e-06	0.000251	CcSEcCtD
Vandetanib—Dermatitis—Everolimus—kidney cancer	8.86e-06	0.000251	CcSEcCtD
Vandetanib—Headache—Vinblastine—kidney cancer	8.85e-06	0.00025	CcSEcCtD
Vandetanib—Headache—Everolimus—kidney cancer	8.82e-06	0.000249	CcSEcCtD
Vandetanib—Abdominal pain—Dactinomycin—kidney cancer	8.8e-06	0.000249	CcSEcCtD
Vandetanib—Body temperature increased—Dactinomycin—kidney cancer	8.8e-06	0.000249	CcSEcCtD
Vandetanib—Visual impairment—Capecitabine—kidney cancer	8.79e-06	0.000248	CcSEcCtD
Vandetanib—Asthenia—Sorafenib—kidney cancer	8.76e-06	0.000248	CcSEcCtD
Vandetanib—Hypoglycaemia—Doxorubicin—kidney cancer	8.71e-06	0.000246	CcSEcCtD
Vandetanib—Cardiac failure—Doxorubicin—kidney cancer	8.71e-06	0.000246	CcSEcCtD
Vandetanib—Lethargy—Doxorubicin—kidney cancer	8.67e-06	0.000245	CcSEcCtD
Vandetanib—Decreased appetite—Vincristine—kidney cancer	8.64e-06	0.000244	CcSEcCtD
Vandetanib—Pruritus—Sorafenib—kidney cancer	8.64e-06	0.000244	CcSEcCtD
Vandetanib—Vomiting—Erlotinib—kidney cancer	8.63e-06	0.000244	CcSEcCtD
Vandetanib—Erythema multiforme—Capecitabine—kidney cancer	8.62e-06	0.000244	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Gemcitabine—kidney cancer	8.59e-06	0.000243	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Vincristine—kidney cancer	8.58e-06	0.000243	CcSEcCtD
Vandetanib—Fatigue—Vincristine—kidney cancer	8.57e-06	0.000242	CcSEcCtD
Vandetanib—Rash—Erlotinib—kidney cancer	8.56e-06	0.000242	CcSEcCtD
Vandetanib—Dermatitis—Erlotinib—kidney cancer	8.55e-06	0.000242	CcSEcCtD
Vandetanib—Hyponatraemia—Doxorubicin—kidney cancer	8.53e-06	0.000241	CcSEcCtD
Vandetanib—Insomnia—Gemcitabine—kidney cancer	8.53e-06	0.000241	CcSEcCtD
Vandetanib—Eye disorder—Capecitabine—kidney cancer	8.52e-06	0.000241	CcSEcCtD
Vandetanib—Headache—Erlotinib—kidney cancer	8.51e-06	0.00024	CcSEcCtD
Vandetanib—Loss of consciousness—Paclitaxel—kidney cancer	8.5e-06	0.00024	CcSEcCtD
Vandetanib—Pain—Vincristine—kidney cancer	8.5e-06	0.00024	CcSEcCtD
Vandetanib—Constipation—Vincristine—kidney cancer	8.5e-06	0.00024	CcSEcCtD
Vandetanib—Gastrointestinal haemorrhage—Doxorubicin—kidney cancer	8.5e-06	0.00024	CcSEcCtD
Vandetanib—Paraesthesia—Gemcitabine—kidney cancer	8.47e-06	0.000239	CcSEcCtD
Vandetanib—Cardiac disorder—Capecitabine—kidney cancer	8.47e-06	0.000239	CcSEcCtD
Vandetanib—Cough—Paclitaxel—kidney cancer	8.44e-06	0.000239	CcSEcCtD
Vandetanib—Asthenia—Sunitinib—kidney cancer	8.43e-06	0.000238	CcSEcCtD
Vandetanib—Dyspnoea—Gemcitabine—kidney cancer	8.41e-06	0.000238	CcSEcCtD
Vandetanib—Nausea—Vinblastine—kidney cancer	8.39e-06	0.000237	CcSEcCtD
Vandetanib—Convulsion—Paclitaxel—kidney cancer	8.38e-06	0.000237	CcSEcCtD
Vandetanib—Nausea—Everolimus—kidney cancer	8.36e-06	0.000236	CcSEcCtD
Vandetanib—Diarrhoea—Sorafenib—kidney cancer	8.36e-06	0.000236	CcSEcCtD
Vandetanib—Hypertension—Paclitaxel—kidney cancer	8.35e-06	0.000236	CcSEcCtD
Vandetanib—Pruritus—Sunitinib—kidney cancer	8.32e-06	0.000235	CcSEcCtD
Vandetanib—Angiopathy—Capecitabine—kidney cancer	8.28e-06	0.000234	CcSEcCtD
Vandetanib—Chest pain—Paclitaxel—kidney cancer	8.24e-06	0.000233	CcSEcCtD
Vandetanib—Arthralgia—Paclitaxel—kidney cancer	8.24e-06	0.000233	CcSEcCtD
Vandetanib—Mediastinal disorder—Capecitabine—kidney cancer	8.22e-06	0.000232	CcSEcCtD
Vandetanib—Anxiety—Paclitaxel—kidney cancer	8.21e-06	0.000232	CcSEcCtD
Vandetanib—Decreased appetite—Gemcitabine—kidney cancer	8.2e-06	0.000232	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	8.18e-06	0.000231	CcSEcCtD
Vandetanib—Arrhythmia—Capecitabine—kidney cancer	8.15e-06	0.00023	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Gemcitabine—kidney cancer	8.14e-06	0.00023	CcSEcCtD
Vandetanib—Fatigue—Gemcitabine—kidney cancer	8.13e-06	0.00023	CcSEcCtD
Vandetanib—Gastrointestinal pain—Vincristine—kidney cancer	8.13e-06	0.00023	CcSEcCtD
Vandetanib—Cardiac arrest—Doxorubicin—kidney cancer	8.08e-06	0.000228	CcSEcCtD
Vandetanib—Dizziness—Sorafenib—kidney cancer	8.08e-06	0.000228	CcSEcCtD
Vandetanib—Pain—Gemcitabine—kidney cancer	8.07e-06	0.000228	CcSEcCtD
Vandetanib—Constipation—Gemcitabine—kidney cancer	8.07e-06	0.000228	CcSEcCtD
Vandetanib—Nausea—Erlotinib—kidney cancer	8.07e-06	0.000228	CcSEcCtD
Vandetanib—Alopecia—Capecitabine—kidney cancer	8.06e-06	0.000228	CcSEcCtD
Vandetanib—Dry mouth—Paclitaxel—kidney cancer	8.06e-06	0.000228	CcSEcCtD
Vandetanib—Diarrhoea—Sunitinib—kidney cancer	8.04e-06	0.000227	CcSEcCtD
Vandetanib—Mental disorder—Capecitabine—kidney cancer	7.99e-06	0.000226	CcSEcCtD
Vandetanib—Asthenia—Dactinomycin—kidney cancer	7.98e-06	0.000226	CcSEcCtD
Vandetanib—Blood creatinine increased—Doxorubicin—kidney cancer	7.96e-06	0.000225	CcSEcCtD
Vandetanib—Malnutrition—Capecitabine—kidney cancer	7.94e-06	0.000224	CcSEcCtD
Vandetanib—Dehydration—Doxorubicin—kidney cancer	7.9e-06	0.000223	CcSEcCtD
Vandetanib—Oedema—Paclitaxel—kidney cancer	7.9e-06	0.000223	CcSEcCtD
Vandetanib—Abdominal pain—Vincristine—kidney cancer	7.86e-06	0.000222	CcSEcCtD
Vandetanib—Body temperature increased—Vincristine—kidney cancer	7.86e-06	0.000222	CcSEcCtD
Vandetanib—Infection—Paclitaxel—kidney cancer	7.84e-06	0.000222	CcSEcCtD
Vandetanib—Dry skin—Doxorubicin—kidney cancer	7.79e-06	0.00022	CcSEcCtD
Vandetanib—Dysgeusia—Capecitabine—kidney cancer	7.78e-06	0.00022	CcSEcCtD
Vandetanib—Dizziness—Sunitinib—kidney cancer	7.77e-06	0.00022	CcSEcCtD
Vandetanib—Vomiting—Sorafenib—kidney cancer	7.77e-06	0.00022	CcSEcCtD
Vandetanib—Nervous system disorder—Paclitaxel—kidney cancer	7.74e-06	0.000219	CcSEcCtD
Vandetanib—Hypokalaemia—Doxorubicin—kidney cancer	7.73e-06	0.000219	CcSEcCtD
Vandetanib—Thrombocytopenia—Paclitaxel—kidney cancer	7.73e-06	0.000219	CcSEcCtD
Vandetanib—Rash—Sorafenib—kidney cancer	7.7e-06	0.000218	CcSEcCtD
Vandetanib—Dermatitis—Sorafenib—kidney cancer	7.69e-06	0.000218	CcSEcCtD
Vandetanib—Skin disorder—Paclitaxel—kidney cancer	7.67e-06	0.000217	CcSEcCtD
Vandetanib—Headache—Sorafenib—kidney cancer	7.65e-06	0.000216	CcSEcCtD
Vandetanib—Muscle spasms—Capecitabine—kidney cancer	7.63e-06	0.000216	CcSEcCtD
Vandetanib—Diarrhoea—Dactinomycin—kidney cancer	7.61e-06	0.000215	CcSEcCtD
Vandetanib—Nasopharyngitis—Doxorubicin—kidney cancer	7.6e-06	0.000215	CcSEcCtD
Vandetanib—Gastritis—Doxorubicin—kidney cancer	7.52e-06	0.000213	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Doxorubicin—kidney cancer	7.5e-06	0.000212	CcSEcCtD
Vandetanib—Vision blurred—Capecitabine—kidney cancer	7.48e-06	0.000212	CcSEcCtD
Vandetanib—Vomiting—Sunitinib—kidney cancer	7.47e-06	0.000211	CcSEcCtD
Vandetanib—Body temperature increased—Gemcitabine—kidney cancer	7.46e-06	0.000211	CcSEcCtD
Vandetanib—Tremor—Capecitabine—kidney cancer	7.44e-06	0.00021	CcSEcCtD
Vandetanib—Rash—Sunitinib—kidney cancer	7.41e-06	0.000209	CcSEcCtD
Vandetanib—Dermatitis—Sunitinib—kidney cancer	7.4e-06	0.000209	CcSEcCtD
Vandetanib—Headache—Sunitinib—kidney cancer	7.36e-06	0.000208	CcSEcCtD
Vandetanib—Influenza—Doxorubicin—kidney cancer	7.35e-06	0.000208	CcSEcCtD
Vandetanib—Dysphagia—Doxorubicin—kidney cancer	7.35e-06	0.000208	CcSEcCtD
Vandetanib—Nausea—Sorafenib—kidney cancer	7.26e-06	0.000205	CcSEcCtD
Vandetanib—Pancreatitis—Doxorubicin—kidney cancer	7.2e-06	0.000204	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Paclitaxel—kidney cancer	7.19e-06	0.000203	CcSEcCtD
Vandetanib—Insomnia—Paclitaxel—kidney cancer	7.14e-06	0.000202	CcSEcCtD
Vandetanib—Asthenia—Vincristine—kidney cancer	7.13e-06	0.000202	CcSEcCtD
Vandetanib—Paraesthesia—Paclitaxel—kidney cancer	7.09e-06	0.0002	CcSEcCtD
Vandetanib—Vomiting—Dactinomycin—kidney cancer	7.08e-06	0.0002	CcSEcCtD
Vandetanib—Bronchitis—Doxorubicin—kidney cancer	7.06e-06	0.0002	CcSEcCtD
Vandetanib—Dyspnoea—Paclitaxel—kidney cancer	7.04e-06	0.000199	CcSEcCtD
Vandetanib—Rash—Dactinomycin—kidney cancer	7.02e-06	0.000198	CcSEcCtD
Vandetanib—Nausea—Sunitinib—kidney cancer	6.98e-06	0.000197	CcSEcCtD
Vandetanib—Loss of consciousness—Capecitabine—kidney cancer	6.98e-06	0.000197	CcSEcCtD
Vandetanib—Dyspepsia—Paclitaxel—kidney cancer	6.95e-06	0.000196	CcSEcCtD
Vandetanib—Cough—Capecitabine—kidney cancer	6.93e-06	0.000196	CcSEcCtD
Vandetanib—Dysuria—Doxorubicin—kidney cancer	6.87e-06	0.000194	CcSEcCtD
Vandetanib—Neutropenia—Doxorubicin—kidney cancer	6.87e-06	0.000194	CcSEcCtD
Vandetanib—Decreased appetite—Paclitaxel—kidney cancer	6.86e-06	0.000194	CcSEcCtD
Vandetanib—Hypertension—Capecitabine—kidney cancer	6.86e-06	0.000194	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Doxorubicin—kidney cancer	6.83e-06	0.000193	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Paclitaxel—kidney cancer	6.82e-06	0.000193	CcSEcCtD
Vandetanib—Fatigue—Paclitaxel—kidney cancer	6.81e-06	0.000192	CcSEcCtD
Vandetanib—Diarrhoea—Vincristine—kidney cancer	6.8e-06	0.000192	CcSEcCtD
Vandetanib—Pollakiuria—Doxorubicin—kidney cancer	6.79e-06	0.000192	CcSEcCtD
Vandetanib—Asthenia—Gemcitabine—kidney cancer	6.77e-06	0.000191	CcSEcCtD
Vandetanib—Arthralgia—Capecitabine—kidney cancer	6.76e-06	0.000191	CcSEcCtD
Vandetanib—Chest pain—Capecitabine—kidney cancer	6.76e-06	0.000191	CcSEcCtD
Vandetanib—Constipation—Paclitaxel—kidney cancer	6.75e-06	0.000191	CcSEcCtD
Vandetanib—Pain—Paclitaxel—kidney cancer	6.75e-06	0.000191	CcSEcCtD
Vandetanib—Anxiety—Capecitabine—kidney cancer	6.74e-06	0.00019	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	6.71e-06	0.00019	CcSEcCtD
Vandetanib—Photosensitivity reaction—Doxorubicin—kidney cancer	6.7e-06	0.00019	CcSEcCtD
Vandetanib—Pruritus—Gemcitabine—kidney cancer	6.67e-06	0.000189	CcSEcCtD
Vandetanib—Weight decreased—Doxorubicin—kidney cancer	6.65e-06	0.000188	CcSEcCtD
Vandetanib—Hyperglycaemia—Doxorubicin—kidney cancer	6.63e-06	0.000187	CcSEcCtD
Vandetanib—Dry mouth—Capecitabine—kidney cancer	6.61e-06	0.000187	CcSEcCtD
Vandetanib—Nausea—Dactinomycin—kidney cancer	6.61e-06	0.000187	CcSEcCtD
Vandetanib—Pneumonia—Doxorubicin—kidney cancer	6.59e-06	0.000186	CcSEcCtD
Vandetanib—Dizziness—Vincristine—kidney cancer	6.57e-06	0.000186	CcSEcCtD
Vandetanib—Infestation—Doxorubicin—kidney cancer	6.55e-06	0.000185	CcSEcCtD
Vandetanib—Infestation NOS—Doxorubicin—kidney cancer	6.55e-06	0.000185	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	6.49e-06	0.000184	CcSEcCtD
Vandetanib—Oedema—Capecitabine—kidney cancer	6.48e-06	0.000183	CcSEcCtD
Vandetanib—Gastrointestinal pain—Paclitaxel—kidney cancer	6.46e-06	0.000183	CcSEcCtD
Vandetanib—Diarrhoea—Gemcitabine—kidney cancer	6.45e-06	0.000182	CcSEcCtD
Vandetanib—Renal failure—Doxorubicin—kidney cancer	6.44e-06	0.000182	CcSEcCtD
Vandetanib—Infection—Capecitabine—kidney cancer	6.44e-06	0.000182	CcSEcCtD
Vandetanib—Stomatitis—Doxorubicin—kidney cancer	6.38e-06	0.00018	CcSEcCtD
Vandetanib—Conjunctivitis—Doxorubicin—kidney cancer	6.37e-06	0.00018	CcSEcCtD
Vandetanib—Urinary tract infection—Doxorubicin—kidney cancer	6.37e-06	0.00018	CcSEcCtD
Vandetanib—Nervous system disorder—Capecitabine—kidney cancer	6.35e-06	0.00018	CcSEcCtD
Vandetanib—Thrombocytopenia—Capecitabine—kidney cancer	6.34e-06	0.000179	CcSEcCtD
Vandetanib—Vomiting—Vincristine—kidney cancer	6.32e-06	0.000179	CcSEcCtD
Vandetanib—Skin disorder—Capecitabine—kidney cancer	6.29e-06	0.000178	CcSEcCtD
Vandetanib—Rash—Vincristine—kidney cancer	6.27e-06	0.000177	CcSEcCtD
Vandetanib—Dermatitis—Vincristine—kidney cancer	6.26e-06	0.000177	CcSEcCtD
Vandetanib—Haematuria—Doxorubicin—kidney cancer	6.24e-06	0.000177	CcSEcCtD
Vandetanib—Abdominal pain—Paclitaxel—kidney cancer	6.24e-06	0.000176	CcSEcCtD
Vandetanib—Body temperature increased—Paclitaxel—kidney cancer	6.24e-06	0.000176	CcSEcCtD
Vandetanib—Headache—Vincristine—kidney cancer	6.23e-06	0.000176	CcSEcCtD
Vandetanib—Hepatobiliary disease—Doxorubicin—kidney cancer	6.19e-06	0.000175	CcSEcCtD
Vandetanib—Epistaxis—Doxorubicin—kidney cancer	6.18e-06	0.000175	CcSEcCtD
Vandetanib—Sinusitis—Doxorubicin—kidney cancer	6.14e-06	0.000174	CcSEcCtD
Vandetanib—Vomiting—Gemcitabine—kidney cancer	6e-06	0.00017	CcSEcCtD
Vandetanib—Bradycardia—Doxorubicin—kidney cancer	5.99e-06	0.000169	CcSEcCtD
Vandetanib—Rash—Gemcitabine—kidney cancer	5.95e-06	0.000168	CcSEcCtD
Vandetanib—Dermatitis—Gemcitabine—kidney cancer	5.94e-06	0.000168	CcSEcCtD
Vandetanib—Haemoglobin—Doxorubicin—kidney cancer	5.91e-06	0.000167	CcSEcCtD
Vandetanib—Headache—Gemcitabine—kidney cancer	5.91e-06	0.000167	CcSEcCtD
Vandetanib—Nausea—Vincristine—kidney cancer	5.91e-06	0.000167	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Capecitabine—kidney cancer	5.9e-06	0.000167	CcSEcCtD
Vandetanib—Haemorrhage—Doxorubicin—kidney cancer	5.88e-06	0.000166	CcSEcCtD
Vandetanib—Insomnia—Capecitabine—kidney cancer	5.86e-06	0.000166	CcSEcCtD
Vandetanib—Paraesthesia—Capecitabine—kidney cancer	5.82e-06	0.000164	CcSEcCtD
Vandetanib—Urinary tract disorder—Doxorubicin—kidney cancer	5.81e-06	0.000164	CcSEcCtD
Vandetanib—Dyspnoea—Capecitabine—kidney cancer	5.78e-06	0.000163	CcSEcCtD
Vandetanib—Urethral disorder—Doxorubicin—kidney cancer	5.76e-06	0.000163	CcSEcCtD
Vandetanib—Dyspepsia—Capecitabine—kidney cancer	5.7e-06	0.000161	CcSEcCtD
Vandetanib—Visual impairment—Doxorubicin—kidney cancer	5.67e-06	0.00016	CcSEcCtD
Vandetanib—Asthenia—Paclitaxel—kidney cancer	5.67e-06	0.00016	CcSEcCtD
Vandetanib—Decreased appetite—Capecitabine—kidney cancer	5.63e-06	0.000159	CcSEcCtD
Vandetanib—Nausea—Gemcitabine—kidney cancer	5.6e-06	0.000158	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Capecitabine—kidney cancer	5.59e-06	0.000158	CcSEcCtD
Vandetanib—Fatigue—Capecitabine—kidney cancer	5.59e-06	0.000158	CcSEcCtD
Vandetanib—Pruritus—Paclitaxel—kidney cancer	5.59e-06	0.000158	CcSEcCtD
Vandetanib—Erythema multiforme—Doxorubicin—kidney cancer	5.56e-06	0.000157	CcSEcCtD
Vandetanib—Pain—Capecitabine—kidney cancer	5.54e-06	0.000157	CcSEcCtD
Vandetanib—Constipation—Capecitabine—kidney cancer	5.54e-06	0.000157	CcSEcCtD
Vandetanib—Eye disorder—Doxorubicin—kidney cancer	5.49e-06	0.000155	CcSEcCtD
Vandetanib—Cardiac disorder—Doxorubicin—kidney cancer	5.46e-06	0.000154	CcSEcCtD
Vandetanib—Diarrhoea—Paclitaxel—kidney cancer	5.4e-06	0.000153	CcSEcCtD
Vandetanib—Angiopathy—Doxorubicin—kidney cancer	5.33e-06	0.000151	CcSEcCtD
Vandetanib—Gastrointestinal pain—Capecitabine—kidney cancer	5.3e-06	0.00015	CcSEcCtD
Vandetanib—Mediastinal disorder—Doxorubicin—kidney cancer	5.3e-06	0.00015	CcSEcCtD
Vandetanib—Arrhythmia—Doxorubicin—kidney cancer	5.25e-06	0.000148	CcSEcCtD
Vandetanib—Dizziness—Paclitaxel—kidney cancer	5.22e-06	0.000148	CcSEcCtD
Vandetanib—Alopecia—Doxorubicin—kidney cancer	5.2e-06	0.000147	CcSEcCtD
Vandetanib—Mental disorder—Doxorubicin—kidney cancer	5.15e-06	0.000146	CcSEcCtD
Vandetanib—Abdominal pain—Capecitabine—kidney cancer	5.12e-06	0.000145	CcSEcCtD
Vandetanib—Body temperature increased—Capecitabine—kidney cancer	5.12e-06	0.000145	CcSEcCtD
Vandetanib—Malnutrition—Doxorubicin—kidney cancer	5.12e-06	0.000145	CcSEcCtD
Vandetanib—Vomiting—Paclitaxel—kidney cancer	5.02e-06	0.000142	CcSEcCtD
Vandetanib—Dysgeusia—Doxorubicin—kidney cancer	5.01e-06	0.000142	CcSEcCtD
Vandetanib—Rash—Paclitaxel—kidney cancer	4.98e-06	0.000141	CcSEcCtD
Vandetanib—Dermatitis—Paclitaxel—kidney cancer	4.97e-06	0.000141	CcSEcCtD
Vandetanib—Headache—Paclitaxel—kidney cancer	4.95e-06	0.00014	CcSEcCtD
Vandetanib—Muscle spasms—Doxorubicin—kidney cancer	4.92e-06	0.000139	CcSEcCtD
Vandetanib—Vision blurred—Doxorubicin—kidney cancer	4.82e-06	0.000136	CcSEcCtD
Vandetanib—Nausea—Paclitaxel—kidney cancer	4.69e-06	0.000133	CcSEcCtD
Vandetanib—Asthenia—Capecitabine—kidney cancer	4.65e-06	0.000131	CcSEcCtD
Vandetanib—Pruritus—Capecitabine—kidney cancer	4.58e-06	0.00013	CcSEcCtD
Vandetanib—Loss of consciousness—Doxorubicin—kidney cancer	4.5e-06	0.000127	CcSEcCtD
Vandetanib—Cough—Doxorubicin—kidney cancer	4.47e-06	0.000126	CcSEcCtD
Vandetanib—Convulsion—Doxorubicin—kidney cancer	4.43e-06	0.000125	CcSEcCtD
Vandetanib—Diarrhoea—Capecitabine—kidney cancer	4.43e-06	0.000125	CcSEcCtD
Vandetanib—Hypertension—Doxorubicin—kidney cancer	4.42e-06	0.000125	CcSEcCtD
Vandetanib—Arthralgia—Doxorubicin—kidney cancer	4.36e-06	0.000123	CcSEcCtD
Vandetanib—Chest pain—Doxorubicin—kidney cancer	4.36e-06	0.000123	CcSEcCtD
Vandetanib—Anxiety—Doxorubicin—kidney cancer	4.34e-06	0.000123	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	4.33e-06	0.000122	CcSEcCtD
Vandetanib—Dizziness—Capecitabine—kidney cancer	4.29e-06	0.000121	CcSEcCtD
Vandetanib—Dry mouth—Doxorubicin—kidney cancer	4.26e-06	0.00012	CcSEcCtD
Vandetanib—Oedema—Doxorubicin—kidney cancer	4.18e-06	0.000118	CcSEcCtD
Vandetanib—Infection—Doxorubicin—kidney cancer	4.15e-06	0.000117	CcSEcCtD
Vandetanib—Vomiting—Capecitabine—kidney cancer	4.12e-06	0.000116	CcSEcCtD
Vandetanib—Nervous system disorder—Doxorubicin—kidney cancer	4.1e-06	0.000116	CcSEcCtD
Vandetanib—Thrombocytopenia—Doxorubicin—kidney cancer	4.09e-06	0.000116	CcSEcCtD
Vandetanib—Rash—Capecitabine—kidney cancer	4.09e-06	0.000115	CcSEcCtD
Vandetanib—Dermatitis—Capecitabine—kidney cancer	4.08e-06	0.000115	CcSEcCtD
Vandetanib—Headache—Capecitabine—kidney cancer	4.06e-06	0.000115	CcSEcCtD
Vandetanib—Skin disorder—Doxorubicin—kidney cancer	4.06e-06	0.000115	CcSEcCtD
Vandetanib—Nausea—Capecitabine—kidney cancer	3.85e-06	0.000109	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Doxorubicin—kidney cancer	3.81e-06	0.000108	CcSEcCtD
Vandetanib—Insomnia—Doxorubicin—kidney cancer	3.78e-06	0.000107	CcSEcCtD
Vandetanib—Paraesthesia—Doxorubicin—kidney cancer	3.75e-06	0.000106	CcSEcCtD
Vandetanib—Dyspnoea—Doxorubicin—kidney cancer	3.72e-06	0.000105	CcSEcCtD
Vandetanib—Dyspepsia—Doxorubicin—kidney cancer	3.68e-06	0.000104	CcSEcCtD
Vandetanib—Decreased appetite—Doxorubicin—kidney cancer	3.63e-06	0.000103	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Doxorubicin—kidney cancer	3.61e-06	0.000102	CcSEcCtD
Vandetanib—Fatigue—Doxorubicin—kidney cancer	3.6e-06	0.000102	CcSEcCtD
Vandetanib—Constipation—Doxorubicin—kidney cancer	3.57e-06	0.000101	CcSEcCtD
Vandetanib—Pain—Doxorubicin—kidney cancer	3.57e-06	0.000101	CcSEcCtD
Vandetanib—Gastrointestinal pain—Doxorubicin—kidney cancer	3.42e-06	9.65e-05	CcSEcCtD
Vandetanib—Abdominal pain—Doxorubicin—kidney cancer	3.3e-06	9.33e-05	CcSEcCtD
Vandetanib—Body temperature increased—Doxorubicin—kidney cancer	3.3e-06	9.33e-05	CcSEcCtD
Vandetanib—Asthenia—Doxorubicin—kidney cancer	3e-06	8.47e-05	CcSEcCtD
Vandetanib—Pruritus—Doxorubicin—kidney cancer	2.96e-06	8.35e-05	CcSEcCtD
Vandetanib—Diarrhoea—Doxorubicin—kidney cancer	2.86e-06	8.08e-05	CcSEcCtD
Vandetanib—Dizziness—Doxorubicin—kidney cancer	2.76e-06	7.81e-05	CcSEcCtD
Vandetanib—Vomiting—Doxorubicin—kidney cancer	2.66e-06	7.51e-05	CcSEcCtD
Vandetanib—Rash—Doxorubicin—kidney cancer	2.63e-06	7.44e-05	CcSEcCtD
Vandetanib—Dermatitis—Doxorubicin—kidney cancer	2.63e-06	7.44e-05	CcSEcCtD
Vandetanib—Headache—Doxorubicin—kidney cancer	2.62e-06	7.4e-05	CcSEcCtD
Vandetanib—Nausea—Doxorubicin—kidney cancer	2.48e-06	7.01e-05	CcSEcCtD
Vandetanib—ABL1—Immune System—MAPK1—kidney cancer	2.36e-07	8.15e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—MAPK3—kidney cancer	2.35e-07	8.12e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—CTNNB1—kidney cancer	2.34e-07	8.12e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HIF1A—kidney cancer	2.34e-07	8.1e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—MAPK1—kidney cancer	2.34e-07	8.09e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TSC2—kidney cancer	2.34e-07	8.08e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—MAPK1—kidney cancer	2.33e-07	8.06e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—APC—kidney cancer	2.33e-07	8.06e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KIT—kidney cancer	2.33e-07	8.06e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTGS2—kidney cancer	2.33e-07	8.06e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—MAPK3—kidney cancer	2.32e-07	8.04e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—MAPK3—kidney cancer	2.31e-07	8.01e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—RAF1—kidney cancer	2.31e-07	8e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—ABCB1—kidney cancer	2.31e-07	8e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—POMC—kidney cancer	2.3e-07	7.96e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—PIK3CA—kidney cancer	2.3e-07	7.96e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—CDKN1B—kidney cancer	2.29e-07	7.94e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—KRAS—kidney cancer	2.29e-07	7.93e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—ERBB2—kidney cancer	2.29e-07	7.91e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—PTEN—kidney cancer	2.29e-07	7.91e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—KRAS—kidney cancer	2.28e-07	7.9e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—MYC—kidney cancer	2.28e-07	7.9e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—VEGFA—kidney cancer	2.28e-07	7.89e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—RAF1—kidney cancer	2.28e-07	7.89e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—BRAF—kidney cancer	2.27e-07	7.86e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—RELA—kidney cancer	2.27e-07	7.85e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—MAPK3—kidney cancer	2.26e-07	7.82e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—CTNNB1—kidney cancer	2.26e-07	7.82e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MTOR—kidney cancer	2.26e-07	7.81e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—ERBB2—kidney cancer	2.25e-07	7.8e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—CD4—kidney cancer	2.25e-07	7.8e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL2—kidney cancer	2.24e-07	7.77e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GSTM1—kidney cancer	2.24e-07	7.76e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CRABP1—kidney cancer	2.24e-07	7.76e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KDR—kidney cancer	2.24e-07	7.75e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—PTGS2—kidney cancer	2.24e-07	7.74e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—KRAS—kidney cancer	2.23e-07	7.74e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MAPK3—kidney cancer	2.23e-07	7.73e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—KRAS—kidney cancer	2.23e-07	7.73e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—MAPK1—kidney cancer	2.23e-07	7.72e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—RAF1—kidney cancer	2.23e-07	7.72e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TP53—kidney cancer	2.23e-07	7.7e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—KRAS—kidney cancer	2.22e-07	7.7e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MTOR—kidney cancer	2.22e-07	7.7e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—RELA—kidney cancer	2.22e-07	7.69e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—POMC—kidney cancer	2.22e-07	7.68e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—MAPK1—kidney cancer	2.21e-07	7.65e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—KRAS—kidney cancer	2.21e-07	7.64e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—ERBB2—kidney cancer	2.21e-07	7.64e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—MAPK1—kidney cancer	2.2e-07	7.62e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—PTEN—kidney cancer	2.2e-07	7.62e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—KRAS—kidney cancer	2.2e-07	7.62e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—MYC—kidney cancer	2.2e-07	7.61e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—RAF1—kidney cancer	2.2e-07	7.6e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—BRAF—kidney cancer	2.19e-07	7.58e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—RELA—kidney cancer	2.19e-07	7.57e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—JUN—kidney cancer	2.18e-07	7.56e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MTOR—kidney cancer	2.18e-07	7.54e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—ERBB2—kidney cancer	2.17e-07	7.52e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MYC—kidney cancer	2.17e-07	7.52e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—CTNNB1—kidney cancer	2.17e-07	7.5e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MAPK3—kidney cancer	2.16e-07	7.46e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—MAPK1—kidney cancer	2.15e-07	7.44e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MTOR—kidney cancer	2.14e-07	7.42e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CYP1A1—kidney cancer	2.13e-07	7.36e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MAPK1—kidney cancer	2.12e-07	7.35e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—CDKN1B—kidney cancer	2.12e-07	7.33e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—MAPK3—kidney cancer	2.12e-07	7.32e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—PTEN—kidney cancer	2.11e-07	7.31e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—KRAS—kidney cancer	2.11e-07	7.3e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—PIK3CA—kidney cancer	2.1e-07	7.28e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MYC—kidney cancer	2.1e-07	7.26e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—PIK3CA—kidney cancer	2.1e-07	7.26e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—KRAS—kidney cancer	2.09e-07	7.23e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CDKN1B—kidney cancer	2.09e-07	7.23e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ITPR2—kidney cancer	2.08e-07	7.21e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—KRAS—kidney cancer	2.08e-07	7.2e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MAPK3—kidney cancer	2.07e-07	7.17e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KIT—kidney cancer	2.06e-07	7.14e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—APC—kidney cancer	2.06e-07	7.14e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—PIK3CA—kidney cancer	2.05e-07	7.11e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MAPK1—kidney cancer	2.05e-07	7.1e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—PIK3CA—kidney cancer	2.05e-07	7.1e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTGS2—kidney cancer	2.05e-07	7.09e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—PIK3CA—kidney cancer	2.04e-07	7.07e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CDKN1B—kidney cancer	2.04e-07	7.07e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL2—kidney cancer	2.04e-07	7.07e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—MAPK3—kidney cancer	2.04e-07	7.06e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—kidney cancer	2.04e-07	7.05e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—KRAS—kidney cancer	2.03e-07	7.03e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTEN—kidney cancer	2.03e-07	7.03e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—PIK3CA—kidney cancer	2.03e-07	7.02e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—PIK3CA—kidney cancer	2.02e-07	7e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MYC—kidney cancer	2.02e-07	6.98e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—MAPK1—kidney cancer	2.01e-07	6.97e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CDKN1B—kidney cancer	2.01e-07	6.96e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—KRAS—kidney cancer	2.01e-07	6.94e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—CTNNB1—kidney cancer	2e-07	6.92e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL2—kidney cancer	2e-07	6.92e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CCND1—kidney cancer	1.99e-07	6.89e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—JUN—kidney cancer	1.99e-07	6.88e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—kidney cancer	1.98e-07	6.87e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CTNNB1—kidney cancer	1.97e-07	6.83e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MAPK1—kidney cancer	1.97e-07	6.82e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL2—kidney cancer	1.97e-07	6.82e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—POMC—kidney cancer	1.96e-07	6.79e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—kidney cancer	1.96e-07	6.79e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—MAPK3—kidney cancer	1.95e-07	6.76e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—PTEN—kidney cancer	1.95e-07	6.75e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CCND1—kidney cancer	1.95e-07	6.75e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—JUN—kidney cancer	1.95e-07	6.73e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—MAPK1—kidney cancer	1.94e-07	6.71e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—BRAF—kidney cancer	1.94e-07	6.71e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—KRAS—kidney cancer	1.94e-07	6.71e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—PIK3CA—kidney cancer	1.94e-07	6.7e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CTNNB1—kidney cancer	1.93e-07	6.68e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PTEN—kidney cancer	1.92e-07	6.65e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCND1—kidney cancer	1.92e-07	6.64e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—PIK3CA—kidney cancer	1.92e-07	6.64e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—JUN—kidney cancer	1.92e-07	6.63e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—PIK3CA—kidney cancer	1.91e-07	6.62e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—KRAS—kidney cancer	1.9e-07	6.58e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CTNNB1—kidney cancer	1.9e-07	6.58e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ACHE—kidney cancer	1.9e-07	6.58e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTT1—kidney cancer	1.9e-07	6.58e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—MYC—kidney cancer	1.9e-07	6.57e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—RAF1—kidney cancer	1.9e-07	6.57e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—RELA—kidney cancer	1.89e-07	6.54e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MAPK3—kidney cancer	1.88e-07	6.51e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PTEN—kidney cancer	1.88e-07	6.51e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ERBB2—kidney cancer	1.88e-07	6.5e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—PIK3CA—kidney cancer	1.87e-07	6.46e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KRAS—kidney cancer	1.86e-07	6.45e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—MAPK1—kidney cancer	1.86e-07	6.43e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—kidney cancer	1.86e-07	6.42e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PTEN—kidney cancer	1.85e-07	6.41e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MTOR—kidney cancer	1.85e-07	6.41e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—PIK3CA—kidney cancer	1.84e-07	6.38e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—KRAS—kidney cancer	1.83e-07	6.34e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MYC—kidney cancer	1.83e-07	6.34e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—RAF1—kidney cancer	1.83e-07	6.33e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—RELA—kidney cancer	1.82e-07	6.3e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ERBB2—kidney cancer	1.81e-07	6.26e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—MAPK3—kidney cancer	1.8e-07	6.25e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SCARB1—kidney cancer	1.8e-07	6.23e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MAPK1—kidney cancer	1.79e-07	6.2e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTEN—kidney cancer	1.79e-07	6.19e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MTOR—kidney cancer	1.78e-07	6.18e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—kidney cancer	1.78e-07	6.17e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS1—kidney cancer	1.78e-07	6.17e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—PIK3CA—kidney cancer	1.78e-07	6.16e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—KRAS—kidney cancer	1.76e-07	6.07e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.75e-07	6.05e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PSMD7—kidney cancer	1.75e-07	6.05e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—PIK3CA—kidney cancer	1.75e-07	6.05e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CDKN1B—kidney cancer	1.74e-07	6.02e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—kidney cancer	1.74e-07	6.01e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—kidney cancer	1.72e-07	5.96e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—MAPK1—kidney cancer	1.72e-07	5.94e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PIK3CA—kidney cancer	1.71e-07	5.92e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL2—kidney cancer	1.7e-07	5.89e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—kidney cancer	1.7e-07	5.88e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—KRAS—kidney cancer	1.69e-07	5.85e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—PIK3CA—kidney cancer	1.68e-07	5.83e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CDKN1B—kidney cancer	1.68e-07	5.8e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—kidney cancer	1.67e-07	5.79e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MAPK3—kidney cancer	1.67e-07	5.77e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCND1—kidney cancer	1.66e-07	5.74e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—BCHE—kidney cancer	1.66e-07	5.73e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—JUN—kidney cancer	1.65e-07	5.73e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK3—kidney cancer	1.64e-07	5.68e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CTNNB1—kidney cancer	1.64e-07	5.68e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL2—kidney cancer	1.64e-07	5.67e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC5A5—kidney cancer	1.64e-07	5.66e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—KRAS—kidney cancer	1.62e-07	5.61e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MYC—kidney cancer	1.62e-07	5.61e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RAF1—kidney cancer	1.62e-07	5.6e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—PIK3CA—kidney cancer	1.61e-07	5.58e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RELA—kidney cancer	1.61e-07	5.58e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK3—kidney cancer	1.61e-07	5.57e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ERBB2—kidney cancer	1.6e-07	5.54e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PTEN—kidney cancer	1.6e-07	5.54e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCND1—kidney cancer	1.6e-07	5.53e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MYC—kidney cancer	1.6e-07	5.53e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—JUN—kidney cancer	1.59e-07	5.52e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MAPK1—kidney cancer	1.59e-07	5.49e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—POMC—kidney cancer	1.59e-07	5.49e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK3—kidney cancer	1.58e-07	5.48e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CTNNB1—kidney cancer	1.58e-07	5.48e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MTOR—kidney cancer	1.58e-07	5.47e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC2A1—kidney cancer	1.58e-07	5.47e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MYC—kidney cancer	1.56e-07	5.41e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK1—kidney cancer	1.56e-07	5.41e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—PIK3CA—kidney cancer	1.55e-07	5.38e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PTEN—kidney cancer	1.54e-07	5.34e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MYC—kidney cancer	1.54e-07	5.33e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK1—kidney cancer	1.53e-07	5.3e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK1—kidney cancer	1.51e-07	5.21e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—KRAS—kidney cancer	1.5e-07	5.18e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—PIK3CA—kidney cancer	1.49e-07	5.16e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CDKN1B—kidney cancer	1.48e-07	5.13e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KRAS—kidney cancer	1.48e-07	5.11e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL2—kidney cancer	1.45e-07	5.02e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—kidney cancer	1.45e-07	5e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KRAS—kidney cancer	1.44e-07	5e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PIK3CA—kidney cancer	1.43e-07	4.96e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KRAS—kidney cancer	1.42e-07	4.92e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCND1—kidney cancer	1.41e-07	4.9e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—JUN—kidney cancer	1.41e-07	4.89e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CTNNB1—kidney cancer	1.4e-07	4.85e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—kidney cancer	1.39e-07	4.82e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—PIK3CA—kidney cancer	1.38e-07	4.76e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK3—kidney cancer	1.37e-07	4.73e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PTEN—kidney cancer	1.37e-07	4.73e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PIK3CA—kidney cancer	1.36e-07	4.69e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MYC—kidney cancer	1.33e-07	4.6e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PIK3CA—kidney cancer	1.33e-07	4.6e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK3—kidney cancer	1.32e-07	4.56e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTP1—kidney cancer	1.32e-07	4.56e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—kidney cancer	1.31e-07	4.54e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PIK3CA—kidney cancer	1.31e-07	4.52e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK1—kidney cancer	1.3e-07	4.5e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—kidney cancer	1.28e-07	4.45e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MYC—kidney cancer	1.28e-07	4.44e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—kidney cancer	1.26e-07	4.38e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—kidney cancer	1.26e-07	4.38e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PIK3CA—kidney cancer	1.26e-07	4.36e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK1—kidney cancer	1.25e-07	4.34e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ABCB1—kidney cancer	1.25e-07	4.32e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—kidney cancer	1.23e-07	4.27e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KRAS—kidney cancer	1.23e-07	4.25e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTM1—kidney cancer	1.21e-07	4.19e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KRAS—kidney cancer	1.18e-07	4.1e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK3—kidney cancer	1.17e-07	4.04e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.15e-07	3.97e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MYC—kidney cancer	1.13e-07	3.93e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CA—kidney cancer	1.13e-07	3.91e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK1—kidney cancer	1.11e-07	3.84e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTEN—kidney cancer	1.1e-07	3.82e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—kidney cancer	1.09e-07	3.78e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CA—kidney cancer	1.09e-07	3.77e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—kidney cancer	1.05e-07	3.64e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KRAS—kidney cancer	1.05e-07	3.63e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CA—kidney cancer	9.63e-08	3.33e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—kidney cancer	9.32e-08	3.23e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—POMC—kidney cancer	8.56e-08	2.96e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CA—kidney cancer	7.78e-08	2.69e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—kidney cancer	6.83e-08	2.36e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTEN—kidney cancer	5.95e-08	2.06e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CA—kidney cancer	4.2e-08	1.45e-06	CbGpPWpGaD
